Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial

Delrieu, Julien; Vellas, Bruno; Guyonnet, Sophie; Cantet, Christelle; Ovod, Vitaliy; Li, Yan; Bollinger, James; Bateman, Randall; Andrieu, Sandrine

doi:10.1186/s13195-023-01325-3

Alzheimer's Research & Therapy

Table 4 Estimated mean difference between positive and negative participants in 1-, 3-, and 5-year change from baseline on composite Z score for each intervention group compared to the control group

From: Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial

Groups	Estimated difference between positive and negative subjects for each intervention group (95% CI)		P value
Groups	Unadjusted	Adjusted^a	Unadjusted	Adjusted^a
1-year ITT MAPT analysis (n = 483)
Multidomain plus omega 3	0.1677 (-0.0498; 0.3852)	0.1693 (-0.0490; 0.3875)	0.1305	0.1282
Omega 3 alone	0.0255 (-0.1916; 0.2427)	-0.0060 (-0.2277; 0.2156)	0.8176	0.9573
Multidomain plus placebo	0.1237 (-0.0931; 0.3404)	0.1055 (-0.1145; 0.3255)	0.2629	0.3467
1-year per-protocol MAPT analysis (n = 457)
Multidomain plus omega 3	0.2147 (-0.0110; 0.4404)	0.2194 (-0.0061; 0.4450)	0.0623	0.0565
Omega 3 alone	0.0380 (-0.1830; 0.2590)	0.0079 (-0.2170; 0.2327)	0.7356	0.9453
Multidomain plus placebo	0.1207 (-0.1033; 0.3446)	0.0954 (-0.1311; 0.3219)	0.2904	0.4084
3-year ITT MAPT analysis (n = 483)
Multidomain plus omega 3	0.2893 (-0.0301; 0.6087)	0.3067 (-0.0110; 0.6244)	0.0757	0.0584
Omega 3 alone	0.0941 (-0.2253; 0.4135)	0.1063 (-0.2169; 0.4295)	0.5628	0.5181
Multidomain plus placebo	0.1602 (-0.1567; 0.4771)	0.1218 (-0.1969; 0.4406)	0.3209	0.4528
3-year per-protocol MAPT analysis (n = 457)
Multidomain plus omega 3	0.3442 (0.0137; 0.6747)	0.3695 (0.0424; 0.6967)	0.0413	0.0269
Omega 3 alone	0.1038 (-0.2201; 0.4277)	0.1186 (-0.2078; 0.4450)	0.5291	0.4754
Multidomain plus placebo	0.1452 (-0.1810; 0.4714)	0.1008 (-0.2261; 0.4277)	0.3819	0.5447
5-year ITT MAPT-PLUS analysis (n = 483)
Multidomain plus omega 3	0.2932 (-0.1331; 0.7196)	0.2738 (-0.1520; 0.6997)	0.1768	0.2065
Omega 3 alone	-0.0645 (-0.4785; 0.3495)	-0.1297 (-0.5534; 0.2940)	0.7592	0.5471
Multidomain plus placebo	0.0261 (-0.4040; 0.4563)	-0.0475 (-0.4828; 0.3878)	0.9049	0.8300
5-year per-protocol MAPT-PLUS analysis (n = 457)
Multidomain plus omega 3	0.3611 (-0.0784; 0.8006)	0.3479 (-0.0903; 0.7861)	0.1069	0.1191
Omega 3 alone	-0.0635 (-0.4862; 0.3591)	-0.1248 (-0.5571; 0.3075)	0.7674	0.5701
Multidomain plus placebo	0.0045 (-0.4389; 0.4478)	-0.0790 (-0.5277; 0.3697)	0.9841	0.7292

ITT Intention-to-treat, MAPT Multidomain Alzheimer Prevention Trial
^aAnalysis adjusted for age, sex, level of education, APOE ε4 genotype, and clinical dementia rating global score

Back to article page

ISSN: 1758-9193

Contact us

General enquiries: journalsubmissions@springernature.com